BMO Capital initiated coverage of Nurix Therapeutics (NRIX) with an Outperform rating and $35 price target The firm believes the company is poised to deliver significant growth with its protein degradation platform, noting that its BTK degrader, NX-5948, is demonstrating that degradation of the BTK protein can lead to clinical responses in patients that have progressed on prior lines of targeted therapies. The firm views Nurix as “well-positioned for long-term growth” given the size of the current BTK market and the opportunity to expand into new indications, the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics announces PRIME designation for NX-5948 from EMA
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
- Nurix Therapeutics initiated with a Buy at UBS
- Nurix Therapeutics price target raised to $30 from $26 at H.C. Wainwright
- Nurix Therapeutics Appoints Anil Kapur to Board